Biogen Analyst Price Targets

Wall Street analyst price targets and consensus rating for Biogen (BIIB).

Price Target Range — 6 Quarters

Analyst Consensus — 25 Analysts

18Buy

7Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$222Upside to Avg. PT-0.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Reduce	$165→$175
Sep 3, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$225→$245
Aug 25, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$240→$260
Aug 13, 2026	Wolfe Research	Alexandria Hammond	Upgrade	Peer Perform→Outperform	$300
Aug 4, 2026	Mizuho	Salim Syed	PT Raise	Outperform	$221→$241
Aug 3, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$200→$215
Jul 30, 2026	UBS	Michael Yee	PT Raise	Buy	$225→$240
Jul 30, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$237→$251
Jul 30, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$222→$231
Jul 30, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$242→$240
Jul 30, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$245→$248
Jul 30, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$215→$225
Jul 30, 2026	Wedbush	Laura Chico	PT Raise	Neutral	$201→$215
Jul 29, 2026	Barclays	Emily Field	PT Raise	Equal-Weight	$185→$200
Jul 21, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$260→$280
Jul 21, 2026	B of A Securities	Jason Zemansky	PT Cut	Neutral	$217→$215
Jul 13, 2026	Truist Securities	Danielle Brill	Upgrade	Hold→Buy	$190→$235
Jul 8, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Equal-Weight	$224→$222
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$227→$242
Jun 29, 2026	Needham	Ami Fadia	PT Raise	Buy	$255→$256